These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23042584)

  • 21. The Food and Drug Administration's role in promoting consistent labels for generic drugs.
    Duke JD; Kesselheim AS
    JAMA Intern Med; 2014 Aug; 174(8):1213-4. PubMed ID: 24957047
    [No Abstract]   [Full Text] [Related]  

  • 22. Secret safety warnings on medicines: A case study of information access requests.
    Torka M; Mintzes B; Bhasale A; Fabbri A; Perry L; Lexchin J
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):551-555. PubMed ID: 30840349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States.
    Aagaard L; Hansen EH
    Curr Drug Saf; 2013 Jul; 8(3):162-8. PubMed ID: 23914751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 25. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 27. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic Drugs and the Struggle to Compete: The Role of Skinny Labels.
    Boumil MM; Beninger P
    Clin Ther; 2024 May; 46(5):420-423. PubMed ID: 38796336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generics Substitution, Bioequivalence Standards, and International Oversight: Complex Issues Facing the FDA.
    Bate R; Mathur A; Lever HM; Thakur D; Graedon J; Cooperman T; Mason P; Fox ER
    Trends Pharmacol Sci; 2016 Mar; 37(3):184-191. PubMed ID: 26687297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is Bioequivalence a Sufficient Measure of Equivalence?
    Holman A
    J Leg Med; 2019; 39(3):247-261. PubMed ID: 31626574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.
    Seruga B; Sterling L; Wang L; Tannock IF
    J Clin Oncol; 2011 Jan; 29(2):174-85. PubMed ID: 21135271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA post-marketing safety decisions.
    Klein DF
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract]   [Full Text] [Related]  

  • 33. Flight 483 now boarding.
    Czap A
    Altern Med Rev; 2010 Sep; 15(3):183-5. PubMed ID: 21155619
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety labeling on generic drugs is inconsistent, study says.
    Roehr B
    BMJ; 2012 Dec; 345():e8650. PubMed ID: 23261971
    [No Abstract]   [Full Text] [Related]  

  • 35. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug safety special: chasing shadows.
    Frantz S
    Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When do differences in dissolution profiles predict clinical problems?
    Ngo SN
    J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
    [No Abstract]   [Full Text] [Related]  

  • 40. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.